Evidence for association between hepatitis C virus and Parkinson's disease

Neurol Sci. 2017 Nov;38(11):1913-1920. doi: 10.1007/s10072-017-3077-4. Epub 2017 Aug 5.

Abstract

Parkinson's disease (PD) is a globally prevalent neurodegenerative disorder, characterized by progressive neuronal loss in the substantia nigra and formation of Lewy bodies. These pathological characteristics are clinically translated into motor symptoms, such as bradykinesia, rigidity, resting tremors, and postural instability. Emerging data from epidemiological studies suggest a possible association between PD and hepatitis C virus (HCV) infection, which affects up to 71 million individuals worldwide. Preclinical studies have shown that HCV can penetrate and replicate within the brain macrophages and microglial cells, increasing their production of pro-inflammatory cytokines that can directly cause neuronal toxicity. Other studies reported that interferon, previously used to treat HCV infection, can increase the risk of PD through inhibition of the nigrostriatal dopaminergic transmission or induction of neuroinflammation. In this article, we provide a comprehensive review on the possible association between HCV infection and PD and highlight recommendations for further research and practice in this regard.

Keywords: Hepatitis C virus; Interferon; Neurodegeneration; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Hepacivirus*
  • Hepatitis C / complications*
  • Hepatitis C / epidemiology
  • Hepatitis C / physiopathology
  • Hepatitis C / therapy
  • Humans
  • Parkinson Disease / complications*
  • Parkinson Disease / epidemiology
  • Parkinson Disease / physiopathology
  • Parkinson Disease / virology*